Harmony Biosciences Holdings (HRMY) Short term Debt (2021 - 2026)

Harmony Biosciences Holdings has disclosed Short term Debt across 6 years of filings, most recently posting $20.0 million for Q1 2026.

• Short term Debt for Q1 2026 came in at $20.0 million, up 14.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.0 million (up 14.29% YoY), and the FY2025 annual result was $20.0 million, up 23.08% from the prior year.
• Short term Debt came in at $20.0 million for Q1 2026 at Harmony Biosciences Holdings, roughly flat from $20.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $20.0 million in Q3 2025 to a low of $2.0 million in Q1 2022.
• The 5-year median for Short term Debt is $15.0 million (2023), against an average of $12.5 million.
• Across the five-year window, Short term Debt changed 0.0% in 2022 and jumped 650.0% in 2023, its largest moves.
• Harmony Biosciences Holdings' Short term Debt stood at $2.0 million in 2022, then surged by 650.0% to $15.0 million in 2023, then gained by 8.33% to $16.2 million in 2024, then rose by 23.08% to $20.0 million in 2025, then changed by 0.0% to $20.0 million in 2026.
• The last three Short term Debt figures came in at $20.0 million (Q1 2026), $20.0 million (Q4 2025), and $20.0 million (Q3 2025), per Business Quant data.